8-K: BD Reports Strong Q2 FY2026 Results, Raises EPS Guidance

Becton, Dickinson and Company announced robust second quarter fiscal 2026 financial results, exceeding expectations with revenue growth and adjusted diluted EPS, leading to an upward revision of full-year EPS guidance.

Summary

• Becton, Dickinson and Company (BD) reported its second fiscal quarter results ending March 31, 2026.
• Total revenues were $4.7 billion, a 5.2% increase as reported and 2.6% increase on a foreign currency neutral (FXN) basis.
• Reported diluted EPS from continuing operations was $(0.13), while adjusted diluted EPS from continuing operations was $2.90.
• The company executed a $2.0 billion accelerated share repurchase (ASR) program and retired $2.1 billion of debt during the quarter.
• BD is reaffirming its revenue growth guidance and raising its full-year adjusted diluted EPS guidance to a range of $12.52 to $12.72.
• The company completed the spin-off of its former Biosciences and Diagnostic Solutions business and its combination with Waters Corporation on February 9, 2026, with historical results now reflected as discontinued operations.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong operational execution leading to raised guidance, despite significant one-time charges impacting GAAP results.

Positives

• Revenue increased by 5.2% as reported and 2.6% on a foreign currency neutral basis to $4.7 billion in the second quarter.
• Adjusted diluted EPS from continuing operations was $2.90, an increase of 3.9% as reported and 1.1% FXN.
• More than 90% of the business delivered mid-single-digit growth.
• Strong performance from growth platforms and ongoing margin momentum from BD Excellence.
• Full-year adjusted diluted EPS guidance has been raised to $12.52 - $12.72.
• The company executed a $2.0 billion accelerated share repurchase program.
• The company retired $2.1 billion of debt.
• Received three 2026 Best in KLAS Awards for BD Pyxis MedStation ES and BD Alaris Infusion System.

Negatives

• Reported diluted EPS from continuing operations was $(0.13), a significant decrease of 123.6% as reported and 130.9% FXN compared to the prior year.
• Net loss from continuing operations was $(37) million for the quarter.
• Net loss for the quarter was $(311) million, compared to a net income of $308 million in the prior year.
• Integration, restructuring and transaction expenses increased significantly by 471.5% to $533 million for the quarter.
• Operating income decreased by 75.6% to $93 million for the quarter.
• Income from continuing operations before income taxes decreased by 80.5% to $39 million for the quarter.

Risks

• Risks related to macroeconomic conditions and their impact on healthcare spending.
• Potential impact of tariffs and governmental restrictions on trade.
• Disruptions in global transportation networks or supply chain issues.
• Inflationary pressures, currency and interest rate fluctuations, and increased borrowing costs.
• Geopolitical developments in regions like Iran, the Middle East, and Ukraine.
• Competitive factors, including changing customer preferences and new product introductions by competitors.
• Changes in reimbursement practices, coverage policies, and cost containment measures by third-party payers.
• Product efficacy or safety concerns, regulatory actions, product recalls, or field actions.

Future Outlook

The company is reaffirming its revenue growth expectations for the full fiscal year 2026 and has raised its full-year adjusted diluted EPS guidance to a range of $12.52 to $12.72. This outlook is based on first-half performance and improved visibility into the remainder of the year.

Management Comments

• "We delivered a solid second quarter, with revenue, margins and EPS all ahead of our expectations," said Tom Polen, chairman, CEO and president of BD.
• "Execution was broad-based, with more than 90% of the business delivering midsingledigit growth, strong performance from our growth platforms and ongoing margin momentum from BD Excellence."
• "Based on our firsthalf performance and improved visibility into the balance of the year, we are raising our fullyear adjusted EPS guidance and reaffirming our revenue growth expectations."
• "We remain focused on disciplined execution of our New BD strategy, including advancing our commercial and innovation initiatives across key growth platforms, expanding margins, and delivering on our capital allocation framework, all to drive sustainable longterm shareholder value."

Industry Context

StockSavvy.ai notes that BD's performance in Q2 FY2026, particularly its revenue growth and raised EPS guidance, aligns with a trend of resilience in the medical technology sector despite broader economic uncertainties. The company's strategic focus on innovation and margin expansion through initiatives like 'BD Excellence' and its 'New BD' strategy are key differentiators in a competitive landscape.

Comparison to Industry Standards

• BD's reported revenue growth of 5.2% (2.6% FXN) for Q2 FY2026 is generally in line with or slightly above the mid-single-digit growth expected from established players in the diversified medical technology industry.
• The adjusted diluted EPS of $2.90 demonstrates operational efficiency, though the reported GAAP EPS of $(0.13) highlights the impact of significant restructuring and separation costs, a common challenge for large companies undergoing strategic realignments.
• The company's debt retirement of $2.1 billion and ASR program of $2.0 billion indicate a strong focus on capital allocation and shareholder returns, a practice seen among industry leaders aiming to optimize their balance sheets and enhance shareholder value.
• The three Best in KLAS Awards received by BD's products (Pyxis MedStation ES, Alaris Infusion System) underscore the company's strong market position and customer satisfaction in critical healthcare technology segments, often a benchmark for product leadership.

Legal Proceedings

• Product, litigation, and other items resulted in charges of $132 million for the quarter, including $52 million related to various legal matters.

Stakeholder Impact

• Shareholders: Potential for increased value due to raised EPS guidance, debt retirement, and share repurchases.
• Employees: Continued focus on innovation and strategic execution may lead to opportunities and stability.
• Customers: Introduction of new products like the BD CentroVena One Insertion System and strategic partnerships aim to improve patient care and medication management.
• Suppliers: Continued demand for BD products supports supplier relationships, though supply chain risks are noted.

Next Steps

• Continue disciplined execution of the 'New BD' strategy.
• Advance commercial and innovation initiatives across key growth platforms.
• Focus on expanding margins.
• Deliver on the capital allocation framework to drive sustainable long-term shareholder value.

Key Dates

Recommendation

The company demonstrated strong operational performance and raised its guidance, which is positive. However, the significant GAAP loss and substantial restructuring/separation costs, along with ongoing risks in the forward-looking statements, warrant a cautious 'hold' recommendation until these one-time impacts subside and the strategic initiatives show more sustained GAAP profitability.

Keywords

Becton Dickinson, BD, Medical Technology, Q2 FY2026, Financial Results, EPS Guidance, Revenue Growth, Healthcare